*MURANO was a multicentre, open-label, Phase III trial. Treatment complete after 5-week dose-titration period and twenty four 28-day cycles.
†VENCLYXTO 400 mg daily after initial dose-titration period in the absence of disease progression or unacceptable toxicity
‡Rituximab dosing: 375 mg/m2 IV Day 1, Cycle 1 (initiated after the 5-week dose titration schedule); 500 mg/m2 IV Cycles 2-6. Each cycle was 28 days.
§Bendamustine dosing: 70 mg/m2 IV Days 1 and 2, Cycles 1-6. Each cycle was 28 days.
¶Starting Cycle 1, Day 1 of rituximab.
#Assessed using the International Workshop for Chronic Lymphocytic Leukaemia (IwCLL) updated National Cancer Institute-sponsored Working Group (NCI-WG) guidelines (2008).
**uMRD = <1 tumour cell per 10,000 white cells. MRD was evaluated in the peripheral blood and/or bone marrow using ASO-PCR and/or flow cytometry.
2L = Second line; ASO-PCR = Allele-specific oligonucleotide polymerase chain reaction; BR = Bendamustine+ rituximab; BTKi = Bruton's tyrosine kinase inhibitor; CI = Confidence interval; CLL = Chronic lymphocytic leukaemia; CR = Complete remission; CRi = CR with incomplete haematologic recovery; EoCT = End of combination therapy; EoT = End of treatment; FTD = Fixed treatment duration; HR = Hazard ratio; INV = Investigator; IRC = Independent review committee; ITT = Intent-to-treat; IV = Intravenous; MRD = Minimal residual disease; nPR = Nodular partial response; ORR = Overall response rate; OS = Overall survival; PFS = Progression free survival; PR = Partial response; R/R = Relapsed/refractory; SmPC = Summary of product characteristics; TLS = Tumour lysis syndrome; uMRD; Undetectable minimal residual disease; VEN+O = VENCLYXTO+obinutuzumab; VEN+R = VENCLYXTO+rituximab.